Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06169072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients

Study acronym: MagSnow2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 26, 2024 (before its estimated July 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: Sahlgrenska University Hospital to Vastra Gotaland Regionv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.
Trial Details
NCT Number NCT06169072
Lead Sponsor Vastra Gotaland Region
Conditions
(from sponsor)		 Breast Cancer, Sentinel Lymph Node
Related terms Breast Neoplasms
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov